Springer Science & Business Media, Jul 31, 2002 - Medical - 145 pages
Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.
What people are saying - Write a review
We haven't found any reviews in the usual places.
ACEI administration anemia anemia management anemia of chronic anemic angiotensin associated bone marrow cardiovascular chronic renal failure CKD patients correction of anemia darbepoetin alfa dextran diabetic drug effect efficacy end-stage renal disease endogenous erythropoietin EPO dose epoetin erythropoiesis stimulating protein erythropoietin levels erythropoietin therapy ESRD ESRD patients ferritin g/dl hematocrit hematocrit level hemodialysis patients hemoglobin concentration hemoglobin levels improved increase intravenous intravenous iron iron dextran iron sucrose kidney disease Kidney Int kidney transplant recipients left ventricular hypertrophy Macdougall 1C marrow fibrosis Nephrol Dial Transplantation Nephrology normal hematocrit Novel erythropoiesis stimulating Onyekachi Ifudu outcomes parathyroid hormone parathyroidectomy patients with chronic patients with CKD peritoneal dialysis peritoneal dialysis patients pharmacokinetic pre-dialysis receptor recombinant erythropoietin recombinant human erythropoietin renal anemia renal function renal insufficiency renal transplantation response to EPO response to erythropoietin rHuEPO secondary hyperparathyroidism Soc Nephrol sodium ferric gluconate subcutaneous sucrose target hemoglobin uremia week